United Kingdom · Question · Written question
HL HL4944
Tixagevimab/cilgavimab
Introduced
20 January 2023
Last action
8 February 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
8 February 2023
Summary
To ask His Majesty's Government, further to the Written Answer by Lord Markham on 28 November 2022 (HL3401), whether they can provide further information on (1) the additional expert advice received, (2) when this advice was sought and received, (3) who w
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
20 January 2023
Written question
To ask His Majesty's Government, further to the Written Answer by Lord Markham on 28 November 2022 (HL3401), whether they can provide further information on (1) the additional expert advice received, (2) when this advice was sought and received, (3) who w
Source: Lords
8 February 2023
Answer
The expert advice used to determine the cohorts eligible for COVID-19 treatment was led by the Therapeutics Clinical Review Panel. The panel periodically reviews new evidence on the definition and revision of eligible cohorts for COVID-19 therapeutics fro...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-01-20/HL4944
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1569104
- uk · wq-1569104 · source updated 8 February 2023